Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised $252 million by offering 14 million shares at $18, above the upwardly revised range of $16 to $17. The company offered 1 million more shares than anticipated. It originally planned to offer 10 million shares at $14 to $16 before increasing its proposed deal size on Thursday. At pricing, the company commands a fully diluted market cap of $584 million.
Nkarta plans to list on the Nasdaq under the symbol NKTX. Cowen, Evercore ISI, Stifel, and Mizuho Securities acted as lead managers on the deal.
